Opdivo Survival Data Support PD-1 Upfront In Melanoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Results from CheckMate-066 presented at the annual melanoma meeting show Bristol’s Opdivo improves survival over chemotherapy – which performed better than usual due to follow-up treatment with the company’s CTLA-4 inhibitor Yervoy.
You may also be interested in...
Yervoy/Nivolumab May Need Stronger Survival Data To Be First Choice In Melanoma
Bristol’s combo demonstrates similar response rate as PD-1 alone, but with much better survival rates in a small melanoma study presented at ASCO. Due to toxicities, including one death, some say combination would need to shore up survival benefit to become first choice in frontline therapy.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.